| Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? O Alfarisi, WA Alghamdi, MH Al-Shaer, KE Dooley, CA Peloquin Expert Review of Clinical Pharmacology 10 (10), 1027-1036, 2017 | 55 | 2017 |
| Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients MH Al-Shaer, E Rubido, K Cherabuddi, V Venugopalan, K Klinker, ... Journal of Antimicrobial Chemotherapy 75 (12), 3644-3651, 2020 | 51 | 2020 |
| Protein binding of first-line antituberculosis drugs WA Alghamdi, MH Al-Shaer, CA Peloquin Antimicrobial agents and chemotherapy 62 (7), 10.1128/aac. 00641-18, 2018 | 51 | 2018 |
| Perspectives for personalized therapy for patients with multidrug‐resistant tuberculosis C Lange, WA Alghamdi, MH Al‐Shaer, S Brighenti, AH Diacon, ... Journal of internal medicine 284 (2), 163-188, 2018 | 47 | 2018 |
| Meropenem, cefepime, and piperacillin protein binding in patient samples MH Al-Shaer, WA Alghamdi, E Graham, CA Peloquin Therapeutic drug monitoring 42 (1), 129-132, 2020 | 40 | 2020 |
| Population pharmacokinetics of linezolid in tuberculosis patients: dosing regimen simulation and target attainment analysis WA Alghamdi, MH Al-Shaer, G An, A Alsultan, M Kipiani, K Barbakadze, ... Antimicrobial agents and chemotherapy 64 (10), 10.1128/aac. 01174-20, 2020 | 35 | 2020 |
| Cycloserine population pharmacokinetics and pharmacodynamics in patients with tuberculosis WA Alghamdi, A Alsultan, MH Al-Shaer, G An, S Ahmed, Y Alkabab, ... Antimicrobial agents and chemotherapy 63 (5), 10.1128/aac. 00055-19, 2019 | 33 | 2019 |
| Clinical pharmacokinetics and pharmacodynamics of cefepime GM Pais, J Chang, EF Barreto, G Stitt, KJ Downes, MH Alshaer, E Lesnicki, ... Clinical pharmacokinetics 61 (7), 929-953, 2022 | 32 | 2022 |
| Population pharmacokinetics and target attainment of cefepime in critically ill patients and guidance for initial dosing MH Al-Shaer, MN Neely, J Liu, K Cherabuddi, V Venugopalan, ... Antimicrobial agents and chemotherapy 64 (9), 10.1128/aac. 00745-20, 2020 | 29 | 2020 |
| A pharmacology perspective on simultaneous tuberculosis and hepatitis C treatment RR Kempker, WA Alghamdi, MH Al-Shaer, G Burch, CA Peloquin Antimicrobial agents and chemotherapy 63 (12), 10.1128/aac. 01215-19, 2019 | 27 | 2019 |
| A systematic review and meta-analysis of isoniazid pharmacokinetics in healthy volunteers and patients with tuberculosis BL Hong, R D'Cunha, P Li, MH Al-Shaer, WA Alghamdi, G An, C Peloquin Clinical therapeutics 42 (11), e220-e241, 2020 | 25 | 2020 |
| Determination of rifampin concentrations by urine colorimetry and mobile phone readout for personalized dosing in tuberculosis treatment C Szipszky, D Van Aartsen, S Criddle, P Rao, I Zentner, M Justine, ... Journal of the Pediatric Infectious Diseases Society 10 (2), 104-111, 2021 | 23 | 2021 |
| Fluoroquinolones in drug-resistant tuberculosis: culture conversion and pharmacokinetic/pharmacodynamic target attainment to guide dose selection MH Al-Shaer, WA Alghamdi, A Alsultan, G An, S Ahmed, Y Alkabab, ... Antimicrobial agents and chemotherapy 63 (7), 10.1128/aac. 00279-19, 2019 | 21 | 2019 |
| Rifampicin as Adjunct to Colistin Therapy in the Treatment of Multidrug-Resistant Acinetobacter baumannii M Al-Shaer, LH Nazer, M Kherallah Annals of Pharmacotherapy 48 (6), 766-771, 2014 | 21 | 2014 |
| Cycloserine and linezolid for tuberculosis meningitis: pharmacokinetic evidence of potential usefulness RR Kempker, AGC Smith, T Avaliani, M Gujabidze, T Bakuradze, ... Clinical Infectious Diseases 75 (4), 682-689, 2022 | 20 | 2022 |
| Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar MH Al-Shaer, H Mansour, H Elewa, P Salameh, F Iqbal BMC infectious diseases 17, 1-6, 2017 | 18 | 2017 |
| Population pharmacokinetics and significant under-dosing of anti-tuberculosis medications in people with HIV and critical illness PS Rao, CC Moore, AA Mbonde, E Nuwagira, P Orikiriza, D Nyehangane, ... Antibiotics 10 (6), 739, 2021 | 17 | 2021 |
| Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis WA Alghamdi, MH Al-Shaer, M Kipiani, K Barbakadze, L Mikiashvili, ... Journal of Antimicrobial Chemotherapy 76 (4), 1019-1024, 2021 | 16 | 2021 |
| Beta-lactam target attainment and associated outcomes in patients with bloodstream infections MH Alshaer, N Maranchick, KM Alexander, K Manigaba, BR Shoulders, ... International Journal of Antimicrobial Agents 61 (3), 106727, 2023 | 15 | 2023 |
| Using machine learning to define the impact of beta-lactam early and cumulative target attainment on outcomes in intensive care unit patients with hospital-acquired and … MH Alshaer, N Maranchick, C Bai, KL Maguigan, B Shoulders, TW Felton, ... Antimicrobial Agents and Chemotherapy 66 (7), e00563-22, 2022 | 13 | 2022 |
Charles PeloquinProfessor of Pharmacy, University of FloridaEmail verificata su cop.ufl.edu
